About HR+/HER2− advanced breast cancer
Breast cancer can be categorised according to molecular subtype and stage of disease. Advanced breast cancer (aBC) describes both locally advanced and metastatic disease. Around 75% of aBC patients have hormone receptor-positive (HR+) tumours, with over 70% of these patients also having human epidermal growth factor receptor 2-negative (HER2−) tumours.1
Targeting hormone receptors via endocrine therapy has long been a mainstay of treatment for HR+/HER2− aBC. However, endocrine monotherapy typically only delays disease progression for around 1 year.2
The development of targeted therapies, such as CDK4 and 6 inhibitors, has widened options for treatment; in combination with endocrine therapy, they can help improve clinical outcomes.2
aBC, advanced breast cancer; CDK4/6, cyclin-dependent kinases 4 and 6; HER2–, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive.
References
El Sayed R, et al. Front Oncol 2019;9:510.
Matutino A, et al. Curr Oncol 2018;25(Suppl 1):S131–S141.
UK | February 2025 | 442327
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
